MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

60.63 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
87 88 Next >
News headline image
7 Underappreciated Stocks With 25% Return Potential in 2024 ↗
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention. 
Via InvestorPlace
News headline image
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare ↗
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history. 
Via Benzinga
Topics Economy Retirement
News headline image
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest ↗
 
Via Benzinga
News headline image
This Unpopular Dividend Stock Is a Buy ↗
This top pharma stock has fallen too far. 
Via The Motley Fool
News headline image
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
3 Blue-Chip Stocks to Buy at 52-Week Lows in May ↗
These three blue-chip stocks at a 52-week low could provide investors with a good opportunity to open a new position or double an old one. 
Via InvestorPlace
News headline image
S&P 500 Earnings Dashboard 24Q1 - Saturday, May 25 ↗
Of the 480 companies in the S&P 500 that have reported earnings to date for 24Q1, 77.9% reported above analyst expectations. This compares to a long-term average of 66%. 
Via Talk Markets
Topics Stocks
News headline image
Retail Earnings & Consumer Spending: A Closer Look ↗
The U.S. economy is chugging along, with growth moderately decelerating under the Fed’s tight monetary policy. Most of the Q1 earnings season is behind us, with results from 481 S&P 500 companies... 
Via Talk Markets
Topics Economy Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... 
Via Benzinga
News headline image
Bonds Break Down And Send Everyone To Cash ↗
This situation is where the danger, the opportunity, and the action are right now. 
Via Talk Markets
News headline image
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
From Bristol Myers Squibb
Via Business Wire
News headline image
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M ↗
A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous... 
Via Benzinga
News headline image
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Stock I Wouldn't Touch With a 10-Foot Pole ↗
This stock isn't as safe as it seems, and now isn't the time to dabble. 
Via The Motley Fool
News headline image
3 Bargain Stocks to Buy Now: May 2024 ↗
These bargain stocks to buy provide substantial upside since they are trading at a significant discount to their historical multiples. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys. 
Via MarketBeat
News headline image
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst ↗
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine,... 
Via Benzinga
News headline image
Walmart Earnings And The State Of The Consumer ↗
​​​​​​​This earnings season showed a notable acceleration in the earnings growth pace, which produces a reassuring earnings backdrop for the market. 
Via Talk Markets
News headline image
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma ↗
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high... 
Via Benzinga
News headline image
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
News headline image
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story